Accounting for Uncertainty in Decision Analytic Models Using Rank Preserving Structural Failure Time Modeling: Application to Parametric Survival Models.

OBJECTIVES Rank Preserving Structural Failure Time models are one of the most commonly used statistical methods to adjust for treatment switching in oncology clinical trials. The method is often applied in a decision analytic model without appropriately accounting for additional uncertainty when determining the allocation of health care resources. The aim of the study is to describe novel approaches to adequately account for uncertainty when using a Rank Preserving Structural Failure Time model in a decision analytic model. METHODS Using two examples, we tested and compared the performance of the novel Test-based method with the resampling bootstrap method and with the conventional approach of no adjustment. In the first example, we simulated life expectancy using a simple decision analytic model based on a hypothetical oncology trial with treatment switching. In the second example, we applied the adjustment method on published data when no individual patient data were available. RESULTS Mean estimates of overall and incremental life expectancy were similar across methods. However, the bootstrapped and test-based estimates consistently produced greater estimates of uncertainty compared with the estimate without any adjustment applied. Similar results were observed when using the test based approach on a published data showing that failing to adjust for uncertainty led to smaller confidence intervals. CONCLUSIONS Both the bootstrapping and test-based approaches provide a solution to appropriately incorporate uncertainty, with the benefit that the latter can implemented by researchers in the absence of individual patient data.

[1]  M. Sculpher,et al.  Decision Modelling for Health Economic Evaluation , 2006 .

[2]  Nicholas R Latimer,et al.  Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.

[3]  Sung-Bae Kim,et al.  Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. , 2015, The New England journal of medicine.

[4]  M. Sculpher,et al.  Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. , 2005, Health economics.

[5]  Mark Sculpher,et al.  REPORT BY THE DECISION SUPPORT UNIT , 2010 .

[6]  J. Robins,et al.  Correcting for non-compliance in randomized trials using rank preserving structural failure time models , 1991 .

[7]  Nicky J Welton,et al.  Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves , 2012, BMC Medical Research Methodology.

[8]  Keith R Abrams,et al.  Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study , 2018, Statistical methods in medical research.

[9]  P C Lambert,et al.  Adjusting for treatment switching in randomised controlled trials – A simulation study and a simplified two-stage method , 2017, Statistical methods in medical research.

[10]  Nicholas R Latimer,et al.  Treatment switching in oncology trials and the acceptability of adjustment methods , 2015, Expert review of pharmacoeconomics & outcomes research.

[11]  R. Motzer,et al.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.

[12]  Sandeep K. Gupta,et al.  Intention-to-treat concept: A review , 2011, Perspectives in clinical research.

[13]  Keith R Abrams,et al.  Adjusting Survival Time Estimates to Account for Treatment Switching in Randomized Controlled Trials—an Economic Evaluation Context , 2014, Medical decision making : an international journal of the Society for Medical Decision Making.

[14]  K. Abrams,et al.  Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study , 2011, BMC medical research methodology.

[15]  R. Herbst,et al.  Estimating long-term survival of PD-L1-expressing, previously treated, non-small cell lung cancer patients who received pembrolizumab in KEYNOTE-001 and -010. , 2017 .

[16]  Gianluca Baio,et al.  Probabilistic sensitivity analysis in health economics , 2015, Statistical methods in medical research.

[17]  Ian R. White,et al.  Randomization-based methods for correcting for treatment changes: examples from the Concorde trial. , 1999, Statistics in medicine.

[18]  J. Robins,et al.  Correcting for Noncompliance and Dependent Censoring in an AIDS Clinical Trial with Inverse Probability of Censoring Weighted (IPCW) Log‐Rank Tests , 2000, Biometrics.